Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 25, pp. 6756 - 6767
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of clinically aggressive diseases associated with poor outcome. Studies that focus specifically...
LEUKEMIA-LYMPHOMA | PHASE-II TRIAL | 3-WEEKLY CHOP CHEMOTHERAPY | AGGRESSIVE LYMPHOMAS | ANTI-CD30 ANTIBODY 5F11 | NON-HODGKINS-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | PROGNOSTIC-SIGNIFICANCE | GENE-EXPRESSION ANALYSIS | HEMATOLOGY | EPSTEIN-BARR-VIRUS | Folic Acid Antagonists - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Animals | Humans | Lymphoma, T-Cell, Peripheral - pathology | Gene Expression Regulation, Neoplastic | Lymphoma, T-Cell, Peripheral - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - epidemiology
LEUKEMIA-LYMPHOMA | PHASE-II TRIAL | 3-WEEKLY CHOP CHEMOTHERAPY | AGGRESSIVE LYMPHOMAS | ANTI-CD30 ANTIBODY 5F11 | NON-HODGKINS-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | PROGNOSTIC-SIGNIFICANCE | GENE-EXPRESSION ANALYSIS | HEMATOLOGY | EPSTEIN-BARR-VIRUS | Folic Acid Antagonists - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Animals | Humans | Lymphoma, T-Cell, Peripheral - pathology | Gene Expression Regulation, Neoplastic | Lymphoma, T-Cell, Peripheral - genetics | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - epidemiology
Journal Article
Nature Genetics, ISSN 1061-4036, 2014, Volume 46, Issue 2, pp. 171 - 175
Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma characterized by generalized lymphadenopathy and frequent...
FREQUENT | ALIGNMENT | GTPASES | PHOSPHORYLATION | FORM | CRYSTAL-STRUCTURE | GENES | GENETICS & HEREDITY | TET2 | GENOME | FAMILY | NIH 3T3 Cells | Immunoblastic Lymphadenopathy - genetics | Jurkat Cells | Humans | Lymphoma, T-Cell, Peripheral - genetics | Molecular Sequence Data | Bromodeoxyuridine | Isocitrate Dehydrogenase - genetics | Proto-Oncogene Proteins - genetics | rhoA GTP-Binding Protein - genetics | DNA-Binding Proteins - genetics | Sequence Analysis, DNA | Mutation, Missense - genetics | DNA (Cytosine-5-)-Methyltransferases - genetics | Exome - genetics | Animals | Base Sequence | Lymphoma, T-Cell, Peripheral - pathology | Mice | Genetic aspects | Non-Hodgkin's lymphomas | Research | Gene mutations | Health aspects | Risk factors | Medical research | Lymphocytes | Lymphomas | Genomes | Mutation | Gene expression | Tumors
FREQUENT | ALIGNMENT | GTPASES | PHOSPHORYLATION | FORM | CRYSTAL-STRUCTURE | GENES | GENETICS & HEREDITY | TET2 | GENOME | FAMILY | NIH 3T3 Cells | Immunoblastic Lymphadenopathy - genetics | Jurkat Cells | Humans | Lymphoma, T-Cell, Peripheral - genetics | Molecular Sequence Data | Bromodeoxyuridine | Isocitrate Dehydrogenase - genetics | Proto-Oncogene Proteins - genetics | rhoA GTP-Binding Protein - genetics | DNA-Binding Proteins - genetics | Sequence Analysis, DNA | Mutation, Missense - genetics | DNA (Cytosine-5-)-Methyltransferases - genetics | Exome - genetics | Animals | Base Sequence | Lymphoma, T-Cell, Peripheral - pathology | Mice | Genetic aspects | Non-Hodgkin's lymphomas | Research | Gene mutations | Health aspects | Risk factors | Medical research | Lymphocytes | Lymphomas | Genomes | Mutation | Gene expression | Tumors
Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 8, pp. 1901 - 1903
Mutations in isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 (IDH2) occur in most grade 2 and 3 gliomas, secondary glioblastomas, and a subset...
GLIOMAS | PHENOTYPE | LEUKEMIA | HEMATOLOGY | CANCER | Prognosis | Immunoblastic Lymphadenopathy - genetics | Gene Frequency | Humans | Kaplan-Meier Estimate | Lymphoma, T-Cell, Peripheral - genetics | Genotype | Isocitrate Dehydrogenase - genetics | Male | Mutation Rate | Immunoblastic Lymphadenopathy - enzymology | Lymphoma, T-Cell - genetics | Lymphoma, T-Cell, Peripheral - enzymology | Lymphoma, T-Cell - enzymology | Lymphoma, T-Cell, Peripheral - pathology | Lymphoma, T-Cell - pathology | Female | Immunoblastic Lymphadenopathy - pathology | Aged | Mutation | Lymphoid Neoplasia | Brief Report
GLIOMAS | PHENOTYPE | LEUKEMIA | HEMATOLOGY | CANCER | Prognosis | Immunoblastic Lymphadenopathy - genetics | Gene Frequency | Humans | Kaplan-Meier Estimate | Lymphoma, T-Cell, Peripheral - genetics | Genotype | Isocitrate Dehydrogenase - genetics | Male | Mutation Rate | Immunoblastic Lymphadenopathy - enzymology | Lymphoma, T-Cell - genetics | Lymphoma, T-Cell, Peripheral - enzymology | Lymphoma, T-Cell - enzymology | Lymphoma, T-Cell, Peripheral - pathology | Lymphoma, T-Cell - pathology | Female | Immunoblastic Lymphadenopathy - pathology | Aged | Mutation | Lymphoid Neoplasia | Brief Report
Journal Article
Blood, ISSN 0006-4971, 06/2008, Volume 111, Issue 12, pp. 5496 - 5504
The International Peripheral T-Cell Lymphoma Project is a collaborative effort designed to gain better understanding of peripheral T-cell and natural killer...
NON-HODGKINS-LYMPHOMA | MODEL | HEMATOLOGY | PROGNOSIS | EXPRESSION | DISEASE | Lymphoma, Large-Cell, Anaplastic - immunology | Recurrence | Prognosis | Follow-Up Studies | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Male | North America | Protein-Tyrosine Kinases - immunology | Skin Neoplasms - mortality | Adult | Female | Retrospective Studies | Skin Neoplasms - pathology | Diagnosis, Differential | Lymphoma, Large-Cell, Anaplastic - therapy | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Europe | Immunophenotyping | Treatment Outcome | International Cooperation | Receptor Protein-Tyrosine Kinases | Lymphoma, Large-Cell, Anaplastic - mortality | Asia | Lymphoma, T-Cell, Peripheral - pathology | Survival Analysis | Lymphoma, Large-Cell, Anaplastic - pathology | Lymphoma, T-Cell, Peripheral - therapy | Lymphoma, T-Cell, Peripheral - mortality | Lymphoma, T-Cell, Peripheral - immunology
NON-HODGKINS-LYMPHOMA | MODEL | HEMATOLOGY | PROGNOSIS | EXPRESSION | DISEASE | Lymphoma, Large-Cell, Anaplastic - immunology | Recurrence | Prognosis | Follow-Up Studies | Protein-Tyrosine Kinases - metabolism | Humans | Middle Aged | Male | North America | Protein-Tyrosine Kinases - immunology | Skin Neoplasms - mortality | Adult | Female | Retrospective Studies | Skin Neoplasms - pathology | Diagnosis, Differential | Lymphoma, Large-Cell, Anaplastic - therapy | Skin Neoplasms - immunology | Skin Neoplasms - therapy | Europe | Immunophenotyping | Treatment Outcome | International Cooperation | Receptor Protein-Tyrosine Kinases | Lymphoma, Large-Cell, Anaplastic - mortality | Asia | Lymphoma, T-Cell, Peripheral - pathology | Survival Analysis | Lymphoma, Large-Cell, Anaplastic - pathology | Lymphoma, T-Cell, Peripheral - therapy | Lymphoma, T-Cell, Peripheral - mortality | Lymphoma, T-Cell, Peripheral - immunology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2013, Volume 31, Issue 2, pp. 240 - 246
Purpose The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell...
DIAGNOSIS | THERAPY | ONCOLOGY | LYMPHADENOPATHY | MARKER | NON-HODGKINS-LYMPHOMA | CLASSIFICATION | EXPRESSION | CHEMOTHERAPY | Prognosis | Humans | Middle Aged | Immunophenotyping | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Immunoblastic Lymphadenopathy - therapy | Lymphoma, T-Cell, Peripheral - pathology | Aged, 80 and over | Adult | Female | Immunoblastic Lymphadenopathy - pathology | Aged | Lymphoma, T-Cell, Peripheral - therapy | Immunoblastic Lymphadenopathy - immunology | Lymphoma, T-Cell, Peripheral - immunology | Hema25 | ORIGINAL REPORTS | Hema19 | Hema21
DIAGNOSIS | THERAPY | ONCOLOGY | LYMPHADENOPATHY | MARKER | NON-HODGKINS-LYMPHOMA | CLASSIFICATION | EXPRESSION | CHEMOTHERAPY | Prognosis | Humans | Middle Aged | Immunophenotyping | Male | Treatment Outcome | Young Adult | Disease-Free Survival | Immunoblastic Lymphadenopathy - therapy | Lymphoma, T-Cell, Peripheral - pathology | Aged, 80 and over | Adult | Female | Immunoblastic Lymphadenopathy - pathology | Aged | Lymphoma, T-Cell, Peripheral - therapy | Immunoblastic Lymphadenopathy - immunology | Lymphoma, T-Cell, Peripheral - immunology | Hema25 | ORIGINAL REPORTS | Hema19 | Hema21
Journal Article
Critical Reviews in Oncology and Hematology, ISSN 1040-8428, 2008, Volume 68, Issue 3, pp. 264 - 271
Summary Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm clinically characterized by sudden onset of constitutional symptoms,...
Hematology, Oncology and Palliative Medicine | Non-Hodgkin lymphoma | Angioimmunoblastic lymphoma | Peripheral T-cell lymphoma | Autologous transplant | Hypergammaglobulinemia | ALEMTUZUMAB CAMPATH-1H | GENE REARRANGEMENTS | HELPER-CELLS | CHEMOTHERAPY | DYSPROTEINEMIA-TYPE | B-CELL | ONCOLOGY | NON-HODGKINS-LYMPHOMA | ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY | HEMATOLOGY | EPSTEIN-BARR-VIRUS | CD52 EXPRESSION | Cell Proliferation | Lymph Nodes - pathology | Humans | Immunosuppressive Agents - therapeutic use | Dendritic Cells - pathology | Male | Transplantation, Autologous | CD4-Positive T-Lymphocytes - pathology | Lymphoma, T-Cell - metabolism | Stem Cell Transplantation | Epstein-Barr Virus Infections - therapy | B-Lymphocytes - virology | Female | B-Lymphocytes - pathology | B-Lymphocytes - metabolism | Dendritic Cells - metabolism | CD4-Positive T-Lymphocytes - metabolism | Lymph Nodes - metabolism | Survival Rate | Neprilysin - metabolism | Herpesvirus 4, Human | Epstein-Barr Virus Infections - pathology | Lymphoma, T-Cell - drug therapy | Lymphoma, T-Cell - pathology | Epstein-Barr Virus Infections - mortality | Lymphoma, T-Cell - mortality | Thalidomide - therapeutic use | Epstein-Barr Virus Infections - metabolism | Transplantation | Non-Hodgkin's lymphomas | T cells | Gamma globulins | Stem cells
Hematology, Oncology and Palliative Medicine | Non-Hodgkin lymphoma | Angioimmunoblastic lymphoma | Peripheral T-cell lymphoma | Autologous transplant | Hypergammaglobulinemia | ALEMTUZUMAB CAMPATH-1H | GENE REARRANGEMENTS | HELPER-CELLS | CHEMOTHERAPY | DYSPROTEINEMIA-TYPE | B-CELL | ONCOLOGY | NON-HODGKINS-LYMPHOMA | ANGIO-IMMUNOBLASTIC LYMPHADENOPATHY | HEMATOLOGY | EPSTEIN-BARR-VIRUS | CD52 EXPRESSION | Cell Proliferation | Lymph Nodes - pathology | Humans | Immunosuppressive Agents - therapeutic use | Dendritic Cells - pathology | Male | Transplantation, Autologous | CD4-Positive T-Lymphocytes - pathology | Lymphoma, T-Cell - metabolism | Stem Cell Transplantation | Epstein-Barr Virus Infections - therapy | B-Lymphocytes - virology | Female | B-Lymphocytes - pathology | B-Lymphocytes - metabolism | Dendritic Cells - metabolism | CD4-Positive T-Lymphocytes - metabolism | Lymph Nodes - metabolism | Survival Rate | Neprilysin - metabolism | Herpesvirus 4, Human | Epstein-Barr Virus Infections - pathology | Lymphoma, T-Cell - drug therapy | Lymphoma, T-Cell - pathology | Epstein-Barr Virus Infections - mortality | Lymphoma, T-Cell - mortality | Thalidomide - therapeutic use | Epstein-Barr Virus Infections - metabolism | Transplantation | Non-Hodgkin's lymphomas | T cells | Gamma globulins | Stem cells
Journal Article
Blood, ISSN 0006-4971, 03/2017, Volume 129, Issue 9, pp. 1103 - 1112
Peripheral T-cell lymphoma, not otherwise specified, is a broad category of biologically and clinically heterogeneous diseases that cannot be further...
OF-TREATMENT PET/CT | SINGLE-AGENT | ALLOGENEIC TRANSPLANTATION | POSITRON-EMISSION-TOMOGRAPHY | BRENTUXIMAB VEDOTIN | NON-HODGKIN-LYMPHOMA | PHASE-2 CLINICAL-TRIAL | OPEN-LABEL | LENALIDOMIDE MONOTHERAPY | HEMATOLOGY | PREVIOUSLY UNTREATED PATIENTS | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Lymphoma, T-Cell, Peripheral - classification | Lymphoma, T-Cell, Peripheral - therapy | Humans | Lymphoma, T-Cell, Peripheral - genetics
OF-TREATMENT PET/CT | SINGLE-AGENT | ALLOGENEIC TRANSPLANTATION | POSITRON-EMISSION-TOMOGRAPHY | BRENTUXIMAB VEDOTIN | NON-HODGKIN-LYMPHOMA | PHASE-2 CLINICAL-TRIAL | OPEN-LABEL | LENALIDOMIDE MONOTHERAPY | HEMATOLOGY | PREVIOUSLY UNTREATED PATIENTS | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Lymphoma, T-Cell, Peripheral - classification | Lymphoma, T-Cell, Peripheral - therapy | Humans | Lymphoma, T-Cell, Peripheral - genetics
Journal Article
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 19, pp. 2915 - 2923
Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of neoplasms with generally poor clinical outcome. Currently 50% of PTCL cases are not...
EFFECTOR | SURVIVAL | PROFILES | DENDRITIC CELLS | RECOGNITION | SUBTYPES | DIFFERENTIATION | IDENTIFICATION | HEMATOLOGY | PREDICTION | FEATURES | Immunohistochemistry | Prognosis | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lymphoma, T-Cell, Peripheral - genetics | Male | Gene Expression Profiling | Young Adult | Lymphoma, T-Cell, Peripheral - diagnosis | Survival Analysis | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Lymphoma, T-Cell, Peripheral - classification | Aged | Biomarkers, Tumor - genetics | Plenary Paper
EFFECTOR | SURVIVAL | PROFILES | DENDRITIC CELLS | RECOGNITION | SUBTYPES | DIFFERENTIATION | IDENTIFICATION | HEMATOLOGY | PREDICTION | FEATURES | Immunohistochemistry | Prognosis | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lymphoma, T-Cell, Peripheral - genetics | Male | Gene Expression Profiling | Young Adult | Lymphoma, T-Cell, Peripheral - diagnosis | Survival Analysis | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Lymphoma, T-Cell, Peripheral - classification | Aged | Biomarkers, Tumor - genetics | Plenary Paper
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2017, Volume 7, Issue 4, pp. 369 - 379
Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68...
B-CELLS | ISOCHROMOSOME 7Q | GENOMIC LANDSCAPE | BURKITT-LYMPHOMA | ONCOLOGY | THERAPEUTIC TARGETS | GAMMA-DELTA-T | HISTONE-MODIFYING GENES | SOMATIC MUTATIONS | RHOA | H3K36 TRIMETHYLATION | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Child, Preschool | Liver Neoplasms - complications | Male | Lymphoma, T-Cell - complications | Tumor Suppressor Protein p53 - genetics | Young Adult | Splenic Neoplasms - complications | Base Sequence | Tumor Suppressor Proteins - genetics | Adult | Female | Liver Neoplasms - pathology | Child | DNA Helicases - genetics | DNA-Binding Proteins | Histone-Lysine N-Methyltransferase - genetics | Liver Neoplasms - genetics | Splenic Neoplasms - genetics | Lymphoma, T-Cell - genetics | Enhancer of Zeste Homolog 2 Protein | Exome - genetics | Splenic Neoplasms - pathology | Adolescent | Lymphoma, T-Cell - pathology | Aged | Transcription Factors | STAT5B | genetic mutations | HSTL | DERL7 | SETD2 | diffuse large B cell lymphoma | JAK-STAT | germinal center B cell | lymphoma | Burkitt lymphoma | survival | STAT3 | DERL2 | PIK3CD | isochromosome | FFPE exome sequencing | exome sequencing | deep sequencing | mantle cell lymphoma | peripheral T cell lymphoma | angioimmunoblastic T cell lymphoma | high throughput sequencing | copy number | hepatosplenic T cell lymphoma
B-CELLS | ISOCHROMOSOME 7Q | GENOMIC LANDSCAPE | BURKITT-LYMPHOMA | ONCOLOGY | THERAPEUTIC TARGETS | GAMMA-DELTA-T | HISTONE-MODIFYING GENES | SOMATIC MUTATIONS | RHOA | H3K36 TRIMETHYLATION | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Child, Preschool | Liver Neoplasms - complications | Male | Lymphoma, T-Cell - complications | Tumor Suppressor Protein p53 - genetics | Young Adult | Splenic Neoplasms - complications | Base Sequence | Tumor Suppressor Proteins - genetics | Adult | Female | Liver Neoplasms - pathology | Child | DNA Helicases - genetics | DNA-Binding Proteins | Histone-Lysine N-Methyltransferase - genetics | Liver Neoplasms - genetics | Splenic Neoplasms - genetics | Lymphoma, T-Cell - genetics | Enhancer of Zeste Homolog 2 Protein | Exome - genetics | Splenic Neoplasms - pathology | Adolescent | Lymphoma, T-Cell - pathology | Aged | Transcription Factors | STAT5B | genetic mutations | HSTL | DERL7 | SETD2 | diffuse large B cell lymphoma | JAK-STAT | germinal center B cell | lymphoma | Burkitt lymphoma | survival | STAT3 | DERL2 | PIK3CD | isochromosome | FFPE exome sequencing | exome sequencing | deep sequencing | mantle cell lymphoma | peripheral T cell lymphoma | angioimmunoblastic T cell lymphoma | high throughput sequencing | copy number | hepatosplenic T cell lymphoma
Journal Article
Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 22, pp. 5827 - 5834
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphoma. A phase 2 trial was conducted in...
HISTONE DEACETYLASE INHIBITOR | MULTICENTER | CLINICAL-TRIALS | II TRIAL | DIFFERENTIATION | PRALATREXATE | INDUCERS | IDENTIFICATION | HEMATOLOGY | DEPSIPEPTIDE FR901228 | FK228 | Lymphoma, T-Cell, Peripheral - drug therapy | Skin Neoplasms - drug therapy | Humans | Middle Aged | Depsipeptides - pharmacokinetics | Male | Survival Rate | Treatment Outcome | Lymphoma, T-Cell, Cutaneous - drug therapy | Remission Induction | Disease Progression | Tissue Distribution | Antibiotics, Antineoplastic - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Aged, 80 and over | Adult | Female | Aged | Depsipeptides - therapeutic use | Antibiotics, Antineoplastic - pharmacokinetics | Lymphoid Neoplasia | Clinical Trials and Observations
HISTONE DEACETYLASE INHIBITOR | MULTICENTER | CLINICAL-TRIALS | II TRIAL | DIFFERENTIATION | PRALATREXATE | INDUCERS | IDENTIFICATION | HEMATOLOGY | DEPSIPEPTIDE FR901228 | FK228 | Lymphoma, T-Cell, Peripheral - drug therapy | Skin Neoplasms - drug therapy | Humans | Middle Aged | Depsipeptides - pharmacokinetics | Male | Survival Rate | Treatment Outcome | Lymphoma, T-Cell, Cutaneous - drug therapy | Remission Induction | Disease Progression | Tissue Distribution | Antibiotics, Antineoplastic - therapeutic use | Lymphoma, Large-Cell, Anaplastic - drug therapy | Aged, 80 and over | Adult | Female | Aged | Depsipeptides - therapeutic use | Antibiotics, Antineoplastic - pharmacokinetics | Lymphoid Neoplasia | Clinical Trials and Observations
Journal Article
Blood, ISSN 0006-4971, 03/2011, Volume 117, Issue 12, pp. 3402 - 3408
The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22...
PROGNOSTIC-FACTORS | SUBTYPES | SINGLE-CENTER | CLINICAL-FEATURES | OUTCOMES | JAPANESE PATIENTS | HEMATOLOGY | EXPRESSION | CLINICOPATHOLOGICAL FEATURES | Lymphoma, T-Cell, Peripheral - drug therapy | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | International Cooperation | Lymphoma, T-Cell, Peripheral - epidemiology | Young Adult | Lymphoma, T-Cell, Peripheral - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Lymphoma, T-Cell, Peripheral - mortality | Cohort Studies
PROGNOSTIC-FACTORS | SUBTYPES | SINGLE-CENTER | CLINICAL-FEATURES | OUTCOMES | JAPANESE PATIENTS | HEMATOLOGY | EXPRESSION | CLINICOPATHOLOGICAL FEATURES | Lymphoma, T-Cell, Peripheral - drug therapy | Prognosis | Humans | Middle Aged | Male | Treatment Outcome | International Cooperation | Lymphoma, T-Cell, Peripheral - epidemiology | Young Adult | Lymphoma, T-Cell, Peripheral - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Lymphoma, T-Cell, Peripheral - mortality | Cohort Studies
Journal Article